Table 3.
Projected Clinical and Economic Outcomes for the Different Scenarios
| Outcomes | Base Case | Scenario 1 (Threshold, 40%; LISA, 30%; INSURE, 70%) | Scenario 2 (Threshold, 30%; LISA, 30%; INSURE, 70%) |
|---|---|---|---|
| Clinical, n | |||
| Patients | 100 | 100 | 100 |
| Patients getting LISA or INSURE | 0 | 19 | 51 |
| Patients getting surfactant | 32 | 37 | 57 |
| Number of single-dose successes in early rescue | N/A | 10 | 26 |
| BPD patients, n | 14 | 12 | 10 |
| Deaths, n | 2 | 2 | 1 |
| Total doses, mL | 120 | 132 | 194 |
| Duration of stay on MV, hours | 128 | 83 | 54 |
| Patients requiring MV in first 72 hr, n | 32 | 24 | 21 |
|
| |||
| Economics, US $ | |||
| CUROSURF costs | 51,822 | 57,030 | 83,465 |
| Hospitalization (LOS and MV) costs | 9,246,156 | 9,224,109 | 9,229,695 |
| Complication costs | 1,950,392 | 1,714,824 | 1,525,973 |
| Total costs | 11,248,370 | 10,995,963 | 10,839,132 |
BPD, bronchopulmonary dysplasia; INSURE, intubation-surfactant-extubation; LISA, less invasive surfactant administration; MV, mechanical ventilation; N/A, not applicable